Influenza neuraminidase

Influenza and other Respiratory Viruses

Volumn 6, Issue 4, 2012, Pages 245-256

  Air, Gillian M ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Influenza; NA activity; NA antigenicity; NA inhibitors; Neuraminidase

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; SIALIC ACID; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

ALPHA HELIX; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; ENZYME ACTIVITY; ENZYME STRUCTURE; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS HEMAGGLUTINATION;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; INFLUENZA VACCINES; MODELS, MOLECULAR; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PROTEIN CONFORMATION; VIRAL PROTEINS;

EID: 84862003840     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00304.x     Document Type: Article

References (104)

1. Palese P, Schulman J. Inhibitors of viral neuraminidase as potential antiviral drugs; in: Oxford JS, (ed.): Chemoprophylaxis and Virus Infection of the Upper Respiratory Tract. Boca Raton, FL: CRC Press, 1977; 189-205.
2. Colman PM. New antivirals and drug resistance. Annu Rev Biochem 2009; 78:95-118.
3. Saladino R, Barontini M, Crucianelli M et al. Current advances in anti-influenza therapy. Curr Med Chem 2010; 17:2101-2140.
4. Kirchmair J, Distinto S, Liedl KR et al. Development of anti-viral agents using molecular modeling and virtual screening techniques. Infect Disord Drug Targets 2011; 11:64-93.
5. Mitrasinovic PM. Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets 2010; 11:315-326.
6. Air GM, Brouillette WJ. Influenza virus antiviral targets; in: LaFemina R (ed.): Antiviral Research. Washington, DC: ASM Press, 2009; 187-207.
7. Russell RJ, Haire LF, Stevens DJ et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443:45-49.
8. Laver WG. Crystallization and peptide maps of neuraminidase "heads" from H2N2 and H3N2 influenza virus strains. Virology 1978; 86:78-87.
9. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 2008; 82:10493-10501.
10. Harris A, Cardone G, Winkler DC et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci U S A 2006; 103:19123-19127.
11. Barman S, Adhikary L, Chakrabarti AK et al. Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding. J Virol 2004; 78:5258-5269.
12. Jin H, Leser GP, Zhang J, Lamb RA. Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J 1997; 16:1236-1247.
13. Krogh A, Larsson B, von Heijne G, Sonnhammer E. Predicting transmembrane protein topology with a hidden markov model: application to complete genomes. J Mol Biol 2001; 305:567-580.
14. Moller S, Croning M, Apweiler R. Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics 2001; 17:646-653.
15. Blok J, Air GM. Block deletions in the neuraminidase genes from some influenza A viruses of the N1 subtype. Virology 1982; 118:229-234.
16. Els MC, Air GM, Murti KG, Webster RG, Laver WG. An 18-amino acid deletion in an influenza neuraminidase. Virology 1985; 142:241-247.
17. Cuff J, Clamp M, Siddiqui A, Finlay M, Barton G. JPred: a consensus secondary structure prediction server. Bioinformatics 1998; 14:892-893.
18. Munier S, Larcher T, Cormier-Aline F et al. A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens. J Virol 2010; 84:940-952.
19. Kumari K, Gulati S, Smith DF et al. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J 2007; 4:42.
20. Chandrasekaran A, Srinivasan A, Raman R et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol 2008; 26:107-113.
21. Murti KG, Webster RG. Distribution of hemagglutinin and neuraminidase on influenza virions as revealed by immunoelectron microscopy. Virology 1986; 149:36-43.
22. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992; 14:327-332.
23. Tulip WR, Varghese JN, Baker AT et al. Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants. J Mol Biol 1991; 221:487-497.
24. Bossart-Whitaker P, Carson M, Babu YS et al. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2, 3-dehydro-N-acetyl neuraminic acid. J Mol Biol 1993; 232:1069-1083.
25. Burmeister WP, Ruigrok RW, Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 1992; 11:49-56.
26. Air GM, Laver WG. The neuraminidase of influenza virus. Proteins 1989; 6:341-356.
27. De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006; 5:1015-1025.
28. Garman E, Laver G. Controlling influenza by inhibiting the virus's neuraminidase. Curr Drug Targets 2004; 5:119-136.
29. Gong J, Xu W, Zhang J. Structure and functions of influenza virus neuraminidase. Curr Med Chem 2007; 14:113-122.
30. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010; 285:28403-28409.
31. Li Q, Qi J, Zhang W et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 2010; 17:1266-1268.
32. Rudiño-Piñera E, Tunnah P, Lukacik P et al. The crystal structure of type A influenza virus neuraminidase subtype N6 reveals the existence of two separate Neu5Ac binding sites. PDB IDs: 1W1X, 1V0Z, 1W20, 1W21, 2CML. 2006; Available at: (Accessed 24 October 2011).
33. Thompson JD, Higgins DG, Gibson TJ. Improved sensitivity of profile searches through the use of sequence weights and gap excision. Comput Appl Biosci 1994; 10:19-29.
34. Amaro RE, Swift RV, Votapka L et al. Mechanism of 150-cavity formation in influenza neuraminidase. Nat Commun 2011; 2:388.
35. Hirst GK. The agglutination of red cells by allantoic fluid of chick embryos infected with influenza virus. Science 1941; 94:22-23.
36. Gottschalk A. Neuraminic acid: the functional group of some biologically active mucoproteins. Yale J Biol Med 1956; 28:525-537.
37. Laver WG. Structural studies on the protein subunits from three strains of influenza virus. J Mol Biol 1964; 9:109-124.
38. Bucher DJ, Kilbourne ED. A2 (N2) neuraminidase of the X-7 Influenza virus recombinant: determination of molecular size and subunit composition of the active unit. J Virol 1972; 10:60-66.
39. Paterson RG, Lamb RA. Conversion of a class II integral membrane protein into a soluble and efficiently secreted protein: multiple intracellular and extracellular oligomeric and conformational forms. J Cell Biol 1990; 110:999-1011.
40. Colacino JM, Chirgadze NY, Garman E et al. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 1997; 236:66-75.
41. Saito T, Taylor G, Webster R. Steps in maturation of influenza A virus neuraminidase. J Virol 1995; 69:5011-5017.
42. Wu Z, Ethen C, Hickey G, Jiang W. Active 1918 pandemic flu viral neuraminidase has distinct N-glycan profile and is resistant to trypsin digestion. Biochem Biophys Res Commun 2009; 379:749-753.
43. Chong AK, Pegg MS, von Itzstein M. Influenza virus sialidase: effect of calcium on steady-state kinetic parameters. Biochim Biophys Acta 1991; 1077:65-71.
44. Burmeister WP, Cusack S, Ruigrok RW. Calcium is needed for the thermostability of influenza B virus neuraminidase. J Gen Virol 1994; 75:381-388.
45. Smith BJ, Huyton T, Joosten RP et al. Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding. Acta Crystallogr D Biol Crystallogr 2006; 62:947-952.
46. Guo X, Laver W, Vimr E. Catalysis by two sialidases with the same protein fold but different stereochemical courses: a mechanistic comparison of the enzymes from Influenza A Virus and Salmonella typhimurium. J Am Chem Soc 1994; 116:5572-5578.
47. Chong AK, Pegg MS, Taylor NR, von Itzstein M. Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. Eur J Biochem 1992; 207:335-343.
48. Schmidt PM, Attwood RM, Mohr PG, Barrett SA, McKimm-Breschkin JL. A generic system for the expression and purification of soluble and stable influenza neuraminidase. PLoS ONE 2011; 6:e16284.
49. Baum LG, Paulson JC. The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity. Virology 1991; 180:10-15.
50. Kobasa D, Kodihalli S, Luo M et al. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J Virol 1999; 73:6743-6751.
51. Gulati U, Wu W, Gulati S et al. Mismatched hemagglutinin and neuraminidase specificities in recent human H3N2 influenza viruses. Virology 2005; 339:12-20.
52. Mochalova L, Kurova V, Shtyrya Y et al. Oligosaccharide specificity of influenza H1N1 virus neuraminidases. Arch Virol 2007; 152:2047-2057.
53. Drzeniek R, Seto J, Rott R. Characterization of neuraminidases from myxoviruses. Biochim Biophys Acta 1966; 128:547-558.
54. França de Barros J, Sales Alviano D, da Silva MH et al. Characterization of sialidase from an influenza A (H3N2) virus strain: kinetic parameters and substrate specificity. Intervirology 2003; 46:199-206.
55. Corfield AP, Sander-Wewer M, Veh RW, Wember M, Schauer R. The Action of Sialidases on Substrates Containing O-Acetylsialic Acids. Biol Chem Hoppe Seyler 1986; 367:433-439.
56. Laver WG, Colman PM, Webster RG, Hinshaw VS, Air GM. Influenza virus neuraminidase with hemagglutinin activity. Virology 1984; 137:314-323.
57. Webster RG, Air GM, Metzger DW et al. Antigenic structure and variation in an influenza virus N9 neuraminidase. J Virol 1987; 61:2910-2916.
58. Nuss JM, Air GM. Transfer of the hemagglutinin activity of influenza virus neuraminidase subtype N9 into an N2 background. Virology 1991; 183:496-504.
59. Varghese JN, Colman PM, van Donkelaar A et al. Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. Proc Natl Acad Sci U S A 1997; 94:11808-11812.
60. Air GM, Laver WG. Red cells bound to influenza virus N9 neuraminidase are not released by the N9 neuraminidase activity. Virology 1995; 211:278-284.
61. Hausmann J, Kretzschmar E, Garten W, Klenk H-D. N1 neuraminidase of influenza virus A/FPV/Rostock/34 has haemadsorbing activity. J Gen Virol 1995; 7:1719-1728.
62. Uhlendorff J, Matrosovich T, Klenk H-D, Matrosovich M. Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses. Arch Virol 2009; 154:945-957.
63. Burmeister WP, Henrissat B, Bosso C, Cusack S, Ruigrok RW. Influenza B virus neuraminidase can synthesize its own inhibitor. Structure 1993; 1:19-26.
64. Janakiraman MN, White CL, Laver WG, Air GM, Luo M. Structure of influenza virus neuraminidase B/Lee/40 complexed with sialic acid and a dehydro analog at 1.8-A resolution: implications for the catalytic mechanism. Biochemistry 1994; 33:8172-8179.
65. von Itzstein M, Wu WY, Kok GB et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363:418-423.
66. de Clercq E. The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med Res Rev 2011; 31:118-160.
67. Kiso M, Kubo S, Ozawa M et al. Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses. PLoS Pathog 2010; 6:e1000786.
68. Kohno S, Kida H, Mizuguchi M, Shimada J, Group ftS-CS. Efficacy and safety of intravenous peramivir for the treatment of seasonal influenza. Antimicrob Agents Chemother 2010; 54:4568-4574.
69. Weight AK, Haldar J, Alvarez de Cienfuegos L et al. Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus. J Pharm Sci 2011; 100:831-835.
70. Bantia S, Ghate AA, Ananth SL et al. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob Agents Chemother 1998; 42:801-807.
71. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996; 40:40-46.
72. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-317.
73. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328:1272-1275.
74. Gubareva L. Molecular Mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103:199-203.
75. Brookes DW, Miah S, Lackenby A, Hartgroves L, Barclay WS. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J Antimicrob Chemother 2011; 66:466-470.
76. Memoli MJ, Davis AS, Proudfoot K et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis 2011; 203:348-357.
77. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011; 203:25-31.
78. Hamelin M-E, Baz M, Abed Y et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 2010; 6:e1001015.
79. Seibert CW, Kaminski M, Philipp J et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol 2010; 84:11219-11226.
80. Suhaila M, Tang JW, Lee HK et al. Mixtures of Oseltamivir-sensitive and -resistant Pandemic Influenza A/H1N1/2009 Viruses in Immunocompromised Hospitalized Children. Pediatr Infect Dis J 2011; 30:625-627.
81. Saito T, Taylor G, Laver WG, Kawaoka Y, Webster RG. Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase. J Virol 1994; 68:1790-1796.
82. Webster RG, Hinshaw VS, Laver WG. Selection and analysis of antigenic variants of the neuraminidase of N2 influenza viruses with monoclonal antibodies. Virology 1982; 117:93-104.
83. Gulati U, Hwang C-C, Venkatramani L et al. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J Virol 2002; 76:12274-12280.
84. Webster RG, Reay PA, Laver WG. Protection against lethal influenza with neuraminidase. Virology 1988; 164:230-237.
85. Eichelberger M, Golding H, Hess M et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 2008; 26:4299-4303.
86. Johansson BE, Brett IC. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Hum Vaccin 2008; 4:420-424.
87. Subbarao EK, Kawaoka Y, Ryan-Poirier K, Clements ML, Murphy BR. Comparison of different approaches to measuring influenza A virus-specific hemagglutination inhibition antibodies in the presence of serum inhibitors. J Clin Microbiol 1992; 30:996-999.
88. Bright RA, Neuzil KM, Pervikov Y, Palkonyay L. WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008. Vaccine 2009; 27:6366-6369.
89. Feng J, Gulati U, Zhang X et al. Antibody quantity versus quality after influenza vaccination. Vaccine 2009; 27:6358-6362.
90. Air GM, Feng JQ, Chen T et al. Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus. J Clin Immunol 2011; 31:900-912.
91. Sandbulte MR, Gao J, Straight TM, Eichelberger MC. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respi Viruses 2009; 3:233-240.
92. Cate TR, Rayford Y, Niño D et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28:2076-2079.
93. Lambré C, Terzidis H, Greffard A, Webster RG. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990; 135:49-57.
94. Nuss JM, Whitaker PB, Air GM. Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase. Proteins 1993; 15:121-132.
95. Webster RG, Brown LE, Laver WG. Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology 1984; 135:30-42.
96. Malby RL, Tulip WR, Harley VR et al. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 1994; 2:733-746.
97. Tulip WR, Varghese JN, Laver WG, Webster RG, Colman PM. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J Mol Biol 1992; 227:122-148.
98. Venkatramani L, Bochkareva E, Lee JT et al. An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. J Mol Biol 2006; 356:651-663.
99. Lee JT, Air GM. Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5. Virology 2006; 345:424-433.
100. Lee JT, Air GM. Contacts between influenza virus N9 neuraminidase and monoclonal antibody NC10. Virology 2002; 300:255-268.
101. Palese P, Tobita K, Ueda M, Compans RW. Characterization of temperature-sensitive influenza virus mutants defective in neuraminidase. Virology 1974; 61:397-410.
102. Escuret V, Frobert E, Bouscambert-Duchamp M et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 2008; 41:25-28.
103. Moules V, Ferraris O, Terrier O et al. In vitro characterization of naturally occurring influenza H3NA-viruses lacking the NA gene segment: toward a new mechanism of viral resistance? Virology 2010; 404:215-224.
104. Gulati S, Smith DF, Air GM. Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses. Virol J 2009; 6:22.